目的 觀察沙利度胺聯(lián)合柳氮磺吡啶治療強直性脊柱炎對病情活動及功能活動的效果。方法 選擇2013年1月-2015年12月在昆山市第一人民醫(yī)院確診的強直性脊柱炎患者60例作為研究對象，根據(jù)隨機數(shù)字表法分為觀察組與對照組各30例，對照組給予柳氮磺吡啶腸溶片治療，觀察組在此基礎(chǔ)上加用沙利度胺片治療，兩組都治療觀察3個月。結(jié)果 所有患者都完成治療，無嚴重不良反應(yīng)發(fā)生，觀察組與對照組的總有效率分別為96.7%和83.3%，觀察組的總有效率明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。觀察組與對照組治療后的脊柱活動度分別為（51.34±11.94）°和（43.14±9.34）°，都明顯高于治療前的（30.42±13.98）°和（30.45±12.87）°，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；觀察組治療后的脊柱活動度明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。觀察組與對照組治療后的腰椎骨密度T值分別為-0.59±0.32和-0.89±0.13，都明顯高于治療前的-1.21±0.11和1.29±0.15，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療后觀察組的腰椎骨密度也明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。結(jié)論 沙利度胺聯(lián)合柳氮磺吡啶治療強直性脊柱炎有很好的應(yīng)用安全性，能促進腰椎骨密度的恢復，改善脊柱活動度，從而提高治療療效。

Objective To observe the effects of sulfasalazine enteric coated tablets combined with thalidomide in the treatment of ankylosing spondylitis disease activity and functional activities. Methods From January 2013 to December 2015, 60 ankylosing spondylitis patients in our hospital were selected as the research object and were randomly divided into observation group and control group with 30 patients in each group. the control group was given sulfasalazine treatment, the observation group was received thalidomide enteric coated tablets treatment based on the treatment in control group, two groups were treated for 3 months. Results All patients were completed and treatment, and there were no serious adverse reactions occurred during the treatment, the total effective rates of observation group and control group were 96.7% and 83.3% respectively, the total effective rate of observation group was significantly higher than that of control group (P<0.05). The spinal mobility in the observation group and the control group after treatment were (51.34 ±11.94)° and (43.14 ±9.34)°, that were significantly higher than before treatment of (30.42 ±13.98)° and (30.45 ±12.87)° (P<0.05), and the observation group after treatment of spinal activity was significantly higher than the control group (P<0.05). The lumbar bone mineral density of the observation group and control group were -0.59 ±0.32 and -0.89 ±0.13, which were significantly higher than before treatment (-1.21 ±0.11 and 1.29 ±0.15), while after treatment the observation group was higher than the control group (P<0.05). Conclusion Sulfasalazine enteric coated tablets in the treatment of ankylosing spondylitis has good safety, it can promote the bone mineral density of lumbar spine recovery, improve the spinal mobility, so as to improve the curative effect.